Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 6/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6742568 | 1.00 | DRD4 (0.32) | DRD4ALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL6743062 | 0.90 | DRD4 (0.32) | DRD4ALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL10132755 | 0.90 | DRD4 (0.32) | DRD4ALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL6741862 | 0.90 | ALDH1A1 (0.32) | DRD4ALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL10132708 | 0.85 | ALDH1A1 (0.32) | ALDH1A1TP53CYP3A4TSHRSMN1; SMN2 | |
| SCHEMBL6742908 | 0.85 | ALDH1A1 (0.32) | ALDH1A1TP53CYP3A4TSHRSMN1; SMN2 | |
| SCHEMBL13264012 | 0.82 | DRD4 (0.32) | DRD4ALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL6741658 | 0.82 | ALDH1A1 (0.33) | DRD4ALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL14824577 | 0.82 | ALDH1A1 (0.33) | DRD4ALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL17226941 | 0.82 | ALDH1A1 (0.33) | DRD4ALDH1A1TP53CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2374794-B1 | CYCLIC AMINE COMPOUNDS | DAIICHI SANKYO CO LTD (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-8173631-B2 | Cyclic amine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20110319468-A1 | CYCLIC AMINE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| EP-2374794-A1 | CYCLIC AMINE COMPOUNDS | Daiichi Sankyo Company, Limited (JP) | 2011-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319468-A1 | CYCLIC AMINE COMPOUNDS | RYR2, CASR, RYR1 | DRD4 2070/4885ALDH1A1 2584/4885TP53 3433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.